Topological transformation of liposomes by a membrane-affecting domain of recombinant human erythropoietin

References

• Arcasoy M. (2008). The non-haematopoietic biological effects of erythropoietin. Br J Haematol 141:14–31.
   PubMed Web of Science ®Google Scholar
• Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, et al. (2004). Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101:14907–14912.
   PubMed Web of Science ®Google Scholar
• Brines M, Patel N, Villa P, Brines C, Mennini T, et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 105:10925–10930.
   PubMed Web of Science ®Google Scholar
• Carnot P, DeFlandre C. (1906). About the haematopoietic activity of the serum during the regeneration of blood. 143:284–386.
   Google Scholar
• Constantinescu S, Huang L, Nam H, Lodish H. (2001a). The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell 7:377–385.
   PubMed Web of Science ®Google Scholar
• Constantinescu S, Keren T, Socolovsky M, Nam H, Henis Y, Lodish H. (2001b). Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A 98:4379–4384.
   PubMed Web of Science ®Google Scholar
• DePaolis A, Advani J, Sharma B. (1995). Characterization of erythropoietin dimerization. J Pharm Sci 84:1280–1284.
   Google Scholar
• Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E. (1997). Mapping of the active site of recombinant human erythropoietin. Blood 89:493–502.
   PubMed Web of Science ®Google Scholar
• Fisher J. (2003). Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228:1–14.
   PubMed Web of Science ®Google Scholar
• Gursky O. (2002). Complex of human apolipoprotein C-1 with phospholipid: thermodynamic or kinetic stability? Biochemistry 41:7373–7384.
   Google Scholar
• Haroon Z, Amin K, Jiang X, Arcasoy M. (2003). A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 163:993–1000.
   PubMed Web of Science ®Google Scholar
• Hayat MA, Miller SE. (1990) Negative Staining. New York: McGraw-Hill.
   Google Scholar
• Jayaraman S, Gantz D, Gursky O. (2005). Kinetic stabilization and fusion of apolipoprotein A-2:DMPC disks: comparison with apoA-1 and apoC-1. Biophys J 88:2907–2918.
   Google Scholar
• Jelkmann W. (2000). Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol 1:11–31.
   PubMedGoogle Scholar
• Jelkmann W. (2005). Effects of erythropoietin on brain function. Curr Pharm Biotechnol 6:65–79.
   PubMed Web of Science ®Google Scholar
• Jelkmann W. (2007). Erythropoietin after a century of research: younger than ever. Eur J Haematol 78:183–205.
   PubMed Web of Science ®Google Scholar
• Kasi L, Lopez-Berestein G, Mehta K, Rosenblum M, Glenn H, et al. (1984). Distribution and pharmacology of intravenous 99mTc- labeled multilamellar liposomes in rats and mice. Int J Nucl Med Biol 11:35–37.
   PubMedGoogle Scholar
• Kaszuba M, Connah M, McNeil-Watson F, Nobbmann U. (2007). Resolving concentrated particle-size mixtures using dynamic light scattering. Part Part Syst Charact 24:159–162.
   Web of Science ®Google Scholar
• King V, Averill S, Hewazy D, Priestley J, Torup L, Michael-Titus A. (2007). Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur J Neurosci 26:90–100.
   PubMed Web of Science ®Google Scholar
• Koppenhagen F, Storm G, Underberg W. (1998a). Development of a routine analysis method for liposome encapsulated recombinant interleukin-2. J Chromatogr B Biomed Sci Appl 716:285–291.
   Google Scholar
• Koppenhagen F, Visser A, Herron J, Storm G, Crommelin D. (1998b). Interaction of recombinant interleukin-2 with liposomal bilayers. J Pharm Sci 87:707–714.
   PubMed Web of Science ®Google Scholar
• Kuboi R, Mawatari T, Yoshimoto M. (2000). Oxidative refolding of lysozyme assisted by negatively charged liposomes: relationship with lysozyme-mediated fusion of liposomes. J Biosci Bioeng 90:14–19.
   PubMedGoogle Scholar
• Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, et al. (2004). Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239–242.
   PubMed Web of Science ®Google Scholar
• Lykissas M, Korompilias A, Vekris M, Mitsionis G, Sakellariou E, Beris A. (2007). The role of erythropoietin in central and peripheral nerve injury. Clin Neurol Neurosurg 109:639–644.
   PubMedGoogle Scholar
• Maitani Y, Hazama M, Tojo Y, Shimoda N, Nagai T. (1996). Oral administration of recombinant human erythropoietin in liposomes in rats: influence of lipid composition and size of liposomes on bioavailability. J Pharm Sci 85:440–445.
   PubMed Web of Science ®Google Scholar
• Maitani Y, Moriya H, Shimoda N, Takayama K, Nagai T. (1999). Distribution characteristics of entrapped recombinant human erythropoietin in liposomes and its intestinal absorption in rats. Int J Pharm 185:13–22.
   PubMed Web of Science ®Google Scholar
• Matthews D, Topping R, Cass R, Giebel L. (1996). A sequential dimerization mechanism for erythropoietin receptor activation. Proc Natl Acad Sci U S A 93:9471–9476.
   PubMed Web of Science ®Google Scholar
• Mehta R, Gantz D, Gursky O. (2003). Effects of mutations in apolipoprotein C-1 on the reconstitution and kinetic stability of discoidal lipoproteins. Biochemistry 42:4751–4758.
   Google Scholar
• Moriya H, Maitani Y, Shimoda N, Takayama K, Nagai T. (1997). Pharmacokinetic and pharmacological profiles of free and liposomal recombinant human erythropoietin after intravenous and subcutaneous administrations in rats. Pharm Res 14:1621–1628.
   PubMed Web of Science ®Google Scholar
• Nomura F, Nagata M, Inaba T, Hiramatsu H, Hotani H, Takiguchi K. (2001). Capabilities of liposomes for topological transformation. Proc Natl Acad Sci U S A 98:2340–2345.
   PubMed Web of Science ®Google Scholar
• Oku N, Araki R, Araki H, Shibamoto S, Ito F, Nishihara T, et al. (1987). Tumor necrosis factor–induced permeability increase of negatively charged phospholipid vesicles. J Biochem 102:1303–1310.
   Google Scholar
• Oku N, Saito N, Okada S, Watanabe N, Kobayashi Y. (1995). Permeability change of liposomal membrane induced by interleukin-1 alpha. J Biochem 118:832–835.
   PubMed Web of Science ®Google Scholar
• Olson F, Hunt C, Szoka F, Vail W, Papahadjopoulos D. (1979). Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 557:9–23.
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Lopez-Berestein G, Jahns M, Wright K, Kasi L. (1985). Distribution of radiolabeled multilamellar liposomes injected intralymphatically and subcutaneously. Int J Nucl Med Biol 12:261–266.
   PubMedGoogle Scholar
• Sengupta P, Baird B, Holowka D. (2007). Lipid rafts, fluid/fluid phase separation, and their relevance to plasma membrane structure and function. Semin Cell Dev Biol 18:583–590.
   PubMed Web of Science ®Google Scholar
• Seubert N, Royer Y, Staerk J, Kubatzky K, Moucadel V, Krishnakumar S, et al. (2003). Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell 12:1239–1250.
   PubMed Web of Science ®Google Scholar
• Sevcsik E, Pabst G, Jilek A, Lohner K. (2007). How lipids influence the mode of action of membrane-active peptides. Biochim Biophys Acta 1768:2586–2595.
   Google Scholar
• Sevcsik E, Pabst G, Richter W, Danner S, Amenitsch H, Lohner K. (2008). Interaction of LL-37 with model membrane systems of different complexity: influence of the lipid matrix. Biophys J 94:4688–4699.
   Google Scholar
• Sirén A, Fratelli M, Brines M, Goemans C, Casagrande S, et al. (2001). Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 98:4044–4049.
   PubMed Web of Science ®Google Scholar
• Smith K, Bleyer A, Little W, Sane D. (2003). The cardiovascular effects of erythropoietin. Cardiovasc Res 59:538–548.
   PubMed Web of Science ®Google Scholar
• Sułkowskia W, Pentaka D, Nowaka K, Sułkowska A. (2005). The influence of temperature, cholesterol content, and pH on liposome stability. J Mol Struct 744–747:737–747.
   Google Scholar
• Takiguchi K, Nomura F, Inaba T, Takeda S, Saitoh A, Hotani H. (2002). Liposomes possess drastic capabilities for topological transformation. Chemphyschem 3:571–574.
   PubMedGoogle Scholar
• Tilbrook P, Klinken S. (1999). The erythropoietin receptor. Int J Biochem Cell Biol 31:1001–1005.
   Google Scholar
• Van Slooten M, Boerman O, Romøren K, Kedar E, Crommelin D, Storm G. (2001). Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects. Biochim Biophys Acta 1530:134–145.
   PubMed Web of Science ®Google Scholar
• Walde P, Ichikawa S. (2001). Enzymes inside lipid vesicles: preparation, reactivity, and applications. Biomol Eng 18:143–177.
   PubMedGoogle Scholar
• Wang L, Zhang ZG, Gregg SR, Zhang RL, Jiao Z, et al. (2007). The sonic hedgehog pathway mediates carbamylated erythropoietin- enhanced proliferation and differentiation of adult neural progenitor cells. J Biol Chem 282:32462–32470.
   PubMed Web of Science ®Google Scholar
• Zschörnig O, Paasche G, Thieme C, Korb N, Arnold K. (2005). Modulation of lysozyme charge influences interaction with phospholipid vesicles. Coll Surf B Biointerf 42:69–78.
   PubMedGoogle Scholar